Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas

Shin Ichi Miyatake, Shinji Kawabata, Kunio Yokoyama, Toshihiko Kuroiwa, Hiroyuki Michiue, Yoshinori Sakurai, Hiroaki Kumada, Minoru Suzuki, Akira Maruhashi, Mitsunori Kirihata, Koji Ono

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

We have applied boron neutron capture therapy (BNCT) to malignant brain tumors. Here we evaluated the survival benefit of BNCT for recurrent malignant glioma (MG). Since 2002, we have treated 22 cases of recurrent MG with BNCT. Survival time was analyzed with special reference to recursive partitioning analysis (RPA) classification, by Carson et al. (J Clin Oncol 25:2601-2606, 2007). Median survival times (MSTs) after BNCT for all patients and for glioblastoma as on-study histology at recurrence was 10.8 months (n = 22; 95% CI, 7.3-12.8 months) and 9.6 months (n = 19; 95% CI, 6.9-11.4 months), respectively. In our study, MST for the high-risk RPA classes was 9.1 months (n = 11; 95% CI, 4.4-11.0 months). By contrast, the original journal data showed that the MST of the same RPA classes was 4.4 months (n = 129; 95% CI, 3.6-5.4 months). BNCT showed a survival benefit for recurrent MG, especially in the high-risk group.

Original languageEnglish
Pages (from-to)199-206
Number of pages8
JournalJournal of Neuro-Oncology
Volume91
Issue number2
DOIs
Publication statusPublished - 2009

Fingerprint

Boron Neutron Capture Therapy
Glioma
Survival
Glioblastoma
Brain Neoplasms
Histology
Recurrence

Keywords

  • BNCT
  • BPA-PET
  • GBM
  • MG
  • RPA

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

Miyatake, S. I., Kawabata, S., Yokoyama, K., Kuroiwa, T., Michiue, H., Sakurai, Y., ... Ono, K. (2009). Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas. Journal of Neuro-Oncology, 91(2), 199-206. https://doi.org/10.1007/s11060-008-9699-x

Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas. / Miyatake, Shin Ichi; Kawabata, Shinji; Yokoyama, Kunio; Kuroiwa, Toshihiko; Michiue, Hiroyuki; Sakurai, Yoshinori; Kumada, Hiroaki; Suzuki, Minoru; Maruhashi, Akira; Kirihata, Mitsunori; Ono, Koji.

In: Journal of Neuro-Oncology, Vol. 91, No. 2, 2009, p. 199-206.

Research output: Contribution to journalArticle

Miyatake, SI, Kawabata, S, Yokoyama, K, Kuroiwa, T, Michiue, H, Sakurai, Y, Kumada, H, Suzuki, M, Maruhashi, A, Kirihata, M & Ono, K 2009, 'Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas', Journal of Neuro-Oncology, vol. 91, no. 2, pp. 199-206. https://doi.org/10.1007/s11060-008-9699-x
Miyatake, Shin Ichi ; Kawabata, Shinji ; Yokoyama, Kunio ; Kuroiwa, Toshihiko ; Michiue, Hiroyuki ; Sakurai, Yoshinori ; Kumada, Hiroaki ; Suzuki, Minoru ; Maruhashi, Akira ; Kirihata, Mitsunori ; Ono, Koji. / Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas. In: Journal of Neuro-Oncology. 2009 ; Vol. 91, No. 2. pp. 199-206.
@article{37829a8ccbd94985bbdac9d5be9475a5,
title = "Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas",
abstract = "We have applied boron neutron capture therapy (BNCT) to malignant brain tumors. Here we evaluated the survival benefit of BNCT for recurrent malignant glioma (MG). Since 2002, we have treated 22 cases of recurrent MG with BNCT. Survival time was analyzed with special reference to recursive partitioning analysis (RPA) classification, by Carson et al. (J Clin Oncol 25:2601-2606, 2007). Median survival times (MSTs) after BNCT for all patients and for glioblastoma as on-study histology at recurrence was 10.8 months (n = 22; 95{\%} CI, 7.3-12.8 months) and 9.6 months (n = 19; 95{\%} CI, 6.9-11.4 months), respectively. In our study, MST for the high-risk RPA classes was 9.1 months (n = 11; 95{\%} CI, 4.4-11.0 months). By contrast, the original journal data showed that the MST of the same RPA classes was 4.4 months (n = 129; 95{\%} CI, 3.6-5.4 months). BNCT showed a survival benefit for recurrent MG, especially in the high-risk group.",
keywords = "BNCT, BPA-PET, GBM, MG, RPA",
author = "Miyatake, {Shin Ichi} and Shinji Kawabata and Kunio Yokoyama and Toshihiko Kuroiwa and Hiroyuki Michiue and Yoshinori Sakurai and Hiroaki Kumada and Minoru Suzuki and Akira Maruhashi and Mitsunori Kirihata and Koji Ono",
year = "2009",
doi = "10.1007/s11060-008-9699-x",
language = "English",
volume = "91",
pages = "199--206",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas

AU - Miyatake, Shin Ichi

AU - Kawabata, Shinji

AU - Yokoyama, Kunio

AU - Kuroiwa, Toshihiko

AU - Michiue, Hiroyuki

AU - Sakurai, Yoshinori

AU - Kumada, Hiroaki

AU - Suzuki, Minoru

AU - Maruhashi, Akira

AU - Kirihata, Mitsunori

AU - Ono, Koji

PY - 2009

Y1 - 2009

N2 - We have applied boron neutron capture therapy (BNCT) to malignant brain tumors. Here we evaluated the survival benefit of BNCT for recurrent malignant glioma (MG). Since 2002, we have treated 22 cases of recurrent MG with BNCT. Survival time was analyzed with special reference to recursive partitioning analysis (RPA) classification, by Carson et al. (J Clin Oncol 25:2601-2606, 2007). Median survival times (MSTs) after BNCT for all patients and for glioblastoma as on-study histology at recurrence was 10.8 months (n = 22; 95% CI, 7.3-12.8 months) and 9.6 months (n = 19; 95% CI, 6.9-11.4 months), respectively. In our study, MST for the high-risk RPA classes was 9.1 months (n = 11; 95% CI, 4.4-11.0 months). By contrast, the original journal data showed that the MST of the same RPA classes was 4.4 months (n = 129; 95% CI, 3.6-5.4 months). BNCT showed a survival benefit for recurrent MG, especially in the high-risk group.

AB - We have applied boron neutron capture therapy (BNCT) to malignant brain tumors. Here we evaluated the survival benefit of BNCT for recurrent malignant glioma (MG). Since 2002, we have treated 22 cases of recurrent MG with BNCT. Survival time was analyzed with special reference to recursive partitioning analysis (RPA) classification, by Carson et al. (J Clin Oncol 25:2601-2606, 2007). Median survival times (MSTs) after BNCT for all patients and for glioblastoma as on-study histology at recurrence was 10.8 months (n = 22; 95% CI, 7.3-12.8 months) and 9.6 months (n = 19; 95% CI, 6.9-11.4 months), respectively. In our study, MST for the high-risk RPA classes was 9.1 months (n = 11; 95% CI, 4.4-11.0 months). By contrast, the original journal data showed that the MST of the same RPA classes was 4.4 months (n = 129; 95% CI, 3.6-5.4 months). BNCT showed a survival benefit for recurrent MG, especially in the high-risk group.

KW - BNCT

KW - BPA-PET

KW - GBM

KW - MG

KW - RPA

UR - http://www.scopus.com/inward/record.url?scp=57349087805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57349087805&partnerID=8YFLogxK

U2 - 10.1007/s11060-008-9699-x

DO - 10.1007/s11060-008-9699-x

M3 - Article

C2 - 18813875

AN - SCOPUS:57349087805

VL - 91

SP - 199

EP - 206

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 2

ER -